Basic Principles and Drug Development

Introduction to Pharmacology and Professional Relevance

  • Definition of Pharmacology: The study of drugs and their interactions with living systems through chemical processes that alter physiologic function. In a clinical context, these effects are intended to be beneficial or therapeutic.

  • Distinguishing Pharmacology from Pharmacy:

    • Pharmacology: The fundamental study of drug action and effects on the body.
    • Pharmacy: The professional practice of preparing and dispensing medications, as well as monitoring patient responses to those drugs.

  • Core Areas within Pharmacology:

    • Pharmacotherapeutics: The specific use of drugs to prevent, treat, or diagnose various diseases.
    • Pharmacokinetics: The study of "what the body does to the drug," specifically focusing on the absorption, distribution, and elimination of the substance.
    • Pharmacodynamics: The study of "what the drug does to the body," which encompasses the mechanisms by which the drug exerts its physiological effects.
    • Pharmacogenetics: The study of the genetic basis for individual drug responses, primarily investigating person-to-person variations in drug efficacy and safety.
    • Toxicology: The study of the harmful or deleterious effects of chemicals on living systems.

  • Relevance of Pharmacology in Physical Therapy and Rehabilitation:

    • Expectation of Use: It is expected that most patients in a rehabilitation setting will be taking therapeutic medications.
    • Optimal Response: Understanding how drugs affect a patient and the mechanisms behind those effects allows the therapist to adjust treatments to achieve the best possible response during a therapy session.
    • Safety and Interaction: Knowledge of pharmacological properties is essential to avoid or control adverse effects that may arise from direct interactions between a specific physical therapy intervention and the patient’s medication.

Drug Nomenclature and Classification

  • Drug Naming Systems:

    • Chemical Name: Refers specifically to the compound’s chemical structure (e.g., N-acetyl-p-aminophenol).
    • Generic Name (Official Name): Often derived from the chemical name; it is the shortened, official designation for the drug (e.g., acetaminophen).
    • Trade Name (Brand Name): The proprietary name assigned by the individual manufacturer. This name may or may not relate to the chemical or generic name (e.g., Tylenol®).

  • Generic vs. Brand-Name Drugs:

    • Bioequivalence: To be considered equally safe and effective, generic versions must demonstrate bioequivalence to the brand-name counterpart.
    • Criteria for Bioequivalence:
      • Same type and amount of active ingredient(s).
      • Same administration route (e.g., oral, intravenous).
      • Same pharmacokinetic profile.
      • Same therapeutic effects.
    • Inactive Ingredients: Generic and brand-name drugs may contain different inactive ingredients (fillers, dyes, etc.). This is significant because individual patients may respond differently to these inactive components.

Drug Development, Approval, and the FDA Process

  • Developmental Pipeline:

    • In Vitro Studies: Initial testing in laboratory settings to identify lead compounds, efficacy, selectivity, and mechanism of action.
    • Animal Testing: Assessment of drug metabolism and safety. This phase typically lasts an average of 2 years before an Investigational New Drug (IND) application is filed.
    • Clinical Testing (Human Trials):
      • Phase 1: Focuses on safety and pharmacokinetics. Tested on 20–100 healthy subjects.
      • Phase 2: Evaluates if the drug actually works in patients for the intended condition. Tested on 100–200 patients.
      • Phase 3: Large-scale assessment of efficacy and safety, often using double-blind protocols. Tested on 1000–6000 patients.
    • Post-Marketing (Phase 4): Once a New Drug Application (NDA) is approved, Phase 4 involves postmarketing surveillance to monitor the drug's performance and safety in the general population.

  • Timelines and Patents:

    • The clinical testing phases generally span 8–9 years.
    • Patents typically expire 20 years after the initial filing of the application, at which point generic versions may become available.

  • Orphan Drugs:

    • Definition: Drugs developed specifically to treat rare diseases.
    • Facilitation: Because these drugs are often cost-prohibitive to develop, the US Food & Drug Administration (FDA) provides provisions, including additional funding and streamlined processes, to facilitate their development, approval, and production.

Basic Concepts in Drug Therapy and Dose-Response

  • Fundamental Therapeutic Goal: A drug must reach the target cell or tissue and alter its function. The dose must be high enough to be beneficial but low enough to avoid toxicity.

  • Defining Effects:

    • Side Effect (Adverse Effect/Reaction): An unwanted, undesirable effect that occurs within the normal therapeutic dosage range.
    • Toxic Effect: A deleterious and undesired effect, usually occurring at higher doses or due to enhanced drug effects.

  • Dose-Response Relationships:

    • Threshold Dose: The minimum dose required to produce a detectable response.
    • Maximal Effect (Ceiling Effect/Peak Response): The point at which increasing the dose no longer produces an increase in the therapeutic response.
    • Efficacy: The ability of the drug to produce a functional response.
    • Potency: The specific dose required to produce a given response. This is compared using the EC50EC_{50}.

  • Mathematical Variables in Response:

    • EmaxE_{max}: The concentration of the drug producing the maximal possible effect.
    • EC50EC_{50}: The concentration of the drug that produces 50%50\% of the maximal effect.

Drug Safety and Therapeutic Indices

  • Median Doses:

    • ED50ED_{50} (Median Effective Dose): The dose at which 50%50\% of the population responds to the drug in the specified manner.
    • TD50TD_{50} (Median Toxic Dose): The dose at which 50%50\% of the population exhibits a specified toxic or adverse effect.

  • Therapeutic Index (TI):

    • A calculation used to measure the safety of a drug by comparing beneficial effects to toxic effects.
    • Formula: TI=TD50ED50TI = \frac{TD_{50}}{ED_{50}}
    • Interpretation: A higher TI indicates a safer drug. If a TI is low, it means the therapeutic dose is close to the toxic dose, requiring frequent monitoring of drug levels in the patient.

Prescribing and Legal Classifications

  • Off-Label Prescribing: The practice of prescribing a drug for conditions other than those specifically approved by the FDA. This is legal if the prescriber has justification (e.g., research findings) for the specific patient.

  • Prescription vs. Over-the-Counter (OTC):

    • Prescription Drugs: Must be ordered/dispensed by an authorized practitioner (physician, dentist, etc.).
    • OTC Drugs: Direct consumer purchase permitted. Intended for minor problems, deemed safe for use without medical supervision, and have a low chance of toxicity if label directions are followed. They can still interact with other medications.

  • Controlled Substances: Drugs restricted due to their potential for abuse and addiction. Federal classifications take precedence unless state law is more restrictive.

    • Schedule I (C-I): Highest abuse potential; no legal medical use allowed except for research (e.g., heroin, LSD).
    • Schedule II (C-II): High potential for abuse and severe physical/psychologic dependence, but legal for medicinal use (e.g., morphine, amphetamines).
    • Schedule III (C-III): Lower abuse potential than I or II; may lead to moderate physical or strong psychologic dependence (e.g., codeine combinations).
    • Schedule IV (C-IV): Lower abuse potential; limited possibility of dependence (e.g., benzodiazepines, some antianxiety drugs).
    • Schedule V (C-V): Lowest abuse potential; includes certain narcotic cough or antidiarrheal preparations.